Šárka Jíchová1, Libor Kopkan, Zuzana Husková, Šárka Doleželová, Jan Neckář, Petr Kujal, Zdenka Vernerová, Herbert J Kramer, Janusz Sadowski, Elzbieta Kompanowska-Jezierska, Rami N Reddy, John R Falck, John D Imig, Luděk Červenka. 1. aCenter for Experimental Medicine, Institute for Clinical and Experimental Medicine bDepartment of Pathophysiology, 2nd Faculty of Medicine, Charles University cDepartment of Developmental Cardiology, Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic dSection of Nephrology, Medical Policlinic, Department of Medicine, University of Bonn, Bonn, Germany eDepartment of Renal and Body Fluid Physiology, Mossakowski Medical Research Centre, Polish Academy of Science, Warsaw, Poland fDepartment of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas gDepartment of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Abstract
OBJECTIVE: We evaluated the therapeutic effectiveness of a new, orally active epoxyeicosatrienoic acid analog (EET-A) in rats with angiotensin II (ANG II)-dependent malignant hypertension. METHODS: Malignant hypertension was induced in Cyp1a1-Ren-2 transgenic rats by activation of the renin gene using indole-3-carbinol (I3C), a natural xenobiotic. EET-A treatment was started either simultaneously with I3C induction process (early treatment) or 10 days later during established hypertension (late treatment). Blood pressure (BP) (radiotelemetry), indices of renal and cardiac injury, and plasma and kidney levels of the components of the renin-angiotensin system (RAS) were determined. RESULTS: In I3C-induced hypertensive rats, early EET-A treatment attenuated BP increase (to 175 ± 3 versus 193 ± 4 mmHg, P < 0.05, on day 13), reduced albuminuria (15 ± 1 versus 28 ± 2 mg/24 h, P < 0.05), and cardiac hypertrophy as compared with untreated I3C-induced rats. This was associated with suppression of plasma and kidney ANG II levels (48 ± 6 versus 106 ± 9 and 122 ± 19 versus 346 ± 11 fmol ml or g, respectively, P < 0.05) and increases in plasma and kidney angiotensin (1-7) concentrations (84 ± 9 versus 37 ± 6 and 199 ± 12 versus 68 ± 9 fmol/ml or g, respectively, P < 0.05). Remarkably, late EET-A treatment did not lower BP or improve renal and cardiac injury; indices of RAS activity were not affected. CONCLUSION: The new, orally active EET-A attenuated the development of experimental ANG II-dependent malignant hypertension, likely via suppression of the hypertensiogenic axis and augmentation of the vasodilatory/natriuretic axis of RAS.
OBJECTIVE: We evaluated the therapeutic effectiveness of a new, orally active epoxyeicosatrienoic acid analog (EET-A) in rats with angiotensin II (ANG II)-dependent malignant hypertension. METHODS:Malignant hypertension was induced in Cyp1a1-Ren-2 transgenic rats by activation of the renin gene using indole-3-carbinol (I3C), a natural xenobiotic. EET-A treatment was started either simultaneously with I3C induction process (early treatment) or 10 days later during established hypertension (late treatment). Blood pressure (BP) (radiotelemetry), indices of renal and cardiac injury, and plasma and kidney levels of the components of the renin-angiotensin system (RAS) were determined. RESULTS: In I3C-induced hypertensiverats, early EET-A treatment attenuated BP increase (to 175 ± 3 versus 193 ± 4 mmHg, P < 0.05, on day 13), reduced albuminuria (15 ± 1 versus 28 ± 2 mg/24 h, P < 0.05), and cardiac hypertrophy as compared with untreated I3C-induced rats. This was associated with suppression of plasma and kidney ANG II levels (48 ± 6 versus 106 ± 9 and 122 ± 19 versus 346 ± 11 fmol ml or g, respectively, P < 0.05) and increases in plasma and kidney angiotensin (1-7) concentrations (84 ± 9 versus 37 ± 6 and 199 ± 12 versus 68 ± 9 fmol/ml or g, respectively, P < 0.05). Remarkably, late EET-A treatment did not lower BP or improve renal and cardiac injury; indices of RAS activity were not affected. CONCLUSION: The new, orally active EET-A attenuated the development of experimental ANG II-dependent malignant hypertension, likely via suppression of the hypertensiogenic axis and augmentation of the vasodilatory/natriuretic axis of RAS.
Authors: J R Falck; Ravinder Kodela; Rajkumar Manne; Krishnam Raju Atcha; Narender Puli; Narsimhaswamy Dubasi; Vijay L Manthati; Jorge H Capdevila; Xiu-Yu Yi; Daniel H Goldman; Christophe Morisseau; Bruce D Hammock; William B Campbell Journal: J Med Chem Date: 2009-08-27 Impact factor: 7.446
Authors: V Hampl; J Herget; J Bíbová; A Baňasová; Z Husková; Z Vaňourková; Š Jíchová; P Kujal; Z Vernerová; J Sadowski; L Červenka Journal: Physiol Res Date: 2014-09-05 Impact factor: 1.881
Authors: Věra Čertíková Chábová; Petr Kujal; Petra Škaroupková; Zdeňka Varňourková; Šárka Vacková; Zuzana Husková; Soňa Kikerlová; Janusz Sadowski; Elzbieta Kompanowska-Jezierska; Iwona Baranowska; Sung Hee Hwang; Bruce D Hammock; John D Imig; Vladimír Tesař; Ludek Červenka Journal: Kidney Blood Press Res Date: 2018-03-06 Impact factor: 2.687
Authors: Jan Neckář; Md Abdul Hye Khan; Garrett J Gross; Michaela Cyprová; Jaroslav Hrdlička; Alena Kvasilová; John R Falck; William B Campbell; Lenka Sedláková; Šárka Škutová; Veronika Olejníčková; Martina Gregorovičová; David Sedmera; František Kolář; John D Imig Journal: Clin Sci (Lond) Date: 2019-04-29 Impact factor: 6.124
Authors: Agnieszka Walkowska; Luděk Červenka; John D Imig; John R Falck; Janusz Sadowski; Elżbieta Kompanowska-Jezierska Journal: Front Physiol Date: 2021-01-28 Impact factor: 4.566